This program has been designed for physicians and other healthcare professionals involved in the management of patients with CD.
Program Overview
We are entering a new era in the management of Crohn's disease (CD). Two new TNF antagonists have been shown to be effective in treating moderate-to-severe CD -- the fully human adalimumab (now FDA-approved for CD) and the humanized certolizumab pegol (whose approval by the FDA is still pending). Indeed, both agents have also been effective in inducing and maintaining remission in CD patients who had previously been treated with infliximab. In addition, adalimumab was proven to be effective in inducing remission in patients who had lost responsiveness and/or had become intolerant of infliximab.
In light of these exciting results, gastroenterologists who treat CD now have several options to choose from in selecting initial biologic therapy for their patients, as well as selecting alternative therapy for their patients who lose responsiveness or develop intolerance to an initial biologic agent. However, increased options for therapy are accompanied by significant challenges, including finding answers to several pivotal questions:
To provide guidance in answering these questions, we have assembled an expert faculty panel who will present the latest clinical data on biologic agents in the management of CD. In addition, using interesting clinical cases as a focus, the faculty will debate and discuss optimal approaches to the pivotal challenges that are being faced on a daily basis by physicians who manage patients with CD.
Upon completion of this activity, participants should be able to:
All faculty participating in the continuing medical education programs sponsored by The Chicago Medical School at Rosalind Franklin University of Medicine & Science are expected to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentation(s). Full disclosure of faculty relationships were made at the program.
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the sponsorship of Rosalind Franklin University of Medicine & Science. Rosalind Franklin University of Medicine & Science is accredited by the ACCME to provide continuing medical education for physicians.
Rosalind Franklin University of Medicine & Science designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.
*The credit that you receive is based on your user profile.
processing....